The investigational aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo

Clinical Cancer Research

Volumn 19, Issue 7, 2013, Pages 1717-1728

  Zhou, Ning ^a   Singh, Kamini ^a   Mir, Maria C ^a   Parker, Yvonne ^a   Lindner, Daniel ^a   Dreicer, Robert ^a   Ecsedy, Jeffrey A ^b   Zhang, Zhongfa ^c   Teh, Bin T ^d   Almasan, Alexandru ^a   Hansel, Donna E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d National Cancer Center   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; GEMCITABINE; PACLITAXEL;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER PAPILLOMA; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANEUPLOIDY; ANIMALS; APOPTOSIS; AZEPINES; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; DEOXYCYTIDINE; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; NEOPLASM INVASIVENESS; PACLITAXEL; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; TUMOR BURDEN; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877099149     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2383     Document Type: Article

References (50)

1. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78.
2. Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev. 2010 Mar 1. [Epub ahead of print].
3. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 2005;5:42-50. (Pubitemid 40052324)
4. Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54. (Pubitemid 37411723)
5. Slattery SD, Mancini MA, Brinkley BR, Hall RM. Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 2009;8:2984-94.
6. Sesai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63. (Pubitemid 40012993)
7. Bufo P, Sanguedolce F, Tortorella S, Cormio L, Carrieri G, Pannone G. Expression of mitotic kinases phospho-Aurora A and Aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol 2010;25:1371-7.
8. Comperat E, Bieche I, Dargere D, Laurendeau I, Vieillefond A, Benoit G, et al. Gene expression study of Aurora A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 2008;72:873-7.
9. Comperat E, Camparo P, Haus R, Chartier-Kastler E, Radenen B, Richard F, et al. Aurora-A/STK15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419-24. (Pubitemid 46466396)
10. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 2009;11:418-25.
11. Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Hermann FR. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Euro J Surg Oncol 2006;32:439-44.
12. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85. (Pubitemid 41400777)
13. Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, including resistance to taxol. Cancer Cell 2003;3:51-62. (Pubitemid 37443890)
14. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, et al. Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 2006;25:7148-58. (Pubitemid 44764184)
15. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy, and transformation. Nat Genet 1998;20:189-93. (Pubitemid 28455454)
16. Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR. Centrosome amplification and overexpression of Aurora A are early events in ratmammary carcinogenesis. Cancer Res 2002;62:4115-22. (Pubitemid 34791083)
17. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-Aurora 1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62:5168-77. (Pubitemid 35024587)
18. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, et al. Multinuclearity and increased ploidy caused by overexpression of the Aurora- and Ip1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811-6. (Pubitemid 28503674)
19. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999;91:1160-2. (Pubitemid 29330556)
20. Lei Y, Yan S, Ming-De L, Na L, Rui-Fa H. Prognostic significance of Aurora-A expression in human bladder cancer. Acta Histochem 2011;113:514-8.
21. Tomita M, Mori N. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HLTV-1-infected T cells in vitro. Cancer Sci 2010;101:1204-11.
22. Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanahan S, Nawrocki ST, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011;15:2057-70.
23. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202-13.
24. Mahadeven D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, et al. Aurora Ainhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012;18:2210-9.
25. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, et al. The aurora kinase inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 2012;11:763-74.
26. Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, et al. Targeting Aurora kinase A enhances radiation sensitivity of atypical rhabdoid tumor cells. J Neurooncol 2012;107:517-26.
27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
28. Pliarchopoulou K, Laschos K, Pectasides D. Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol. 2010 Sep 13. [Epub ahead of print].
29. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-4. (Pubitemid 41814532)
30. von der Masse H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
31. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 2006;24:5545-51. (Pubitemid 46631335)
32. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
33. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004;20:307-15. (Pubitemid 38262761)
34. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
35. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
36. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93. (Pubitemid 36181903)
37. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010;176:3062-72.
38. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
39. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acid Res 2002;30:207-10. (Pubitemid 34679544)
40. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Junior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010;235:814-24.
41. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Thanasopoulou A, Aravantinos G, et al. Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. J Cancer Res Clin Oncol 2011;137:359-74.
42. Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-79.
43. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-80.
44. Tsuchiya M, Katagiri N, Kuroda T, Kishimoto H, Nishimura K, Kumazawa T, et al. Critical role of the nucleolus in activation of the p53-dependent postmitotic checkpoint. Biochem Biophys Res Commun 2011;407:378-82.
45. Li M, Fang X, Baker DJ, Guo L, Gao X, Wei Z, et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 2010;107:14188-93.
46. Huang YF, Chang MD, Shieh SY. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Mol Cell Biol 2009;29:2935-44.
47. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008;68:8998-9004.
48. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011;87:881-90.
49. VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8:930-9.
50. Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, et al. Targeting Aurora Akinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 2012;131:2693-703.